2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5649 Outcomes of venetoclax-based fixed-duration therapy as a reliable stop for CLL patients in China

Yilin Kong, Shenmiao Yang, PhD2, Shuchao Qin, MBBS3, Yi Miao, MD4, Yi Xia, MD, PhD5, Ling Gao6, Ximing Dai7, Luomengjia Dai8, Ziyuan Zhou9, Tonglu Qiu10, Lei Fan11, Jianyong Li, MD12, Huayuan Zhu, MD, PhD13
1 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
2 National Clinical Research Center for Treatment of Hematologic Disease, Beijing, China, Peking University Institute of Hematology,, Beijing, China, Peking University People's Hospital, Beijing, China
3 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
4 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
5 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
6 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, Jiangsu Province (Suqian) Hospital, Suqian, China
7 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
8 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
9 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
10 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
11 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
12 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, Jiangsu Province (Suqian) Hospital, Suqian, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
13 Jiangsu Cooperative Lymphoma Group, JCLG, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Introduction

Venetoclax(ven)-based fixed-duration regimens has revolutionized the treatment paradigm of chronic lymphocytic leukemia (CLL), offering deep remissions and treatment-free intervals while mitigating the risks associated with continuous therapy. Despite the robust evidence from clinical trials, real-world data on venetoclax-based combinations remain limited, especially in Asian populations. we conducted a multicenter real-world study to describe the clinical characteristics, treatment patterns, venetoclax exposure, efficacy outcomes, and MRD in CLL patients receiving ven-based combination regimens at two academic centers in China. 

Methods

This retrospective, observational, multicenter study included adult patients (≥18 years) with a diagnosis of CLL or small lymphocytic lymphoma (SLL) who received ven-based combination therapy at two academic medical centers in China. Both treatment-naïve (TN) and relapsed/refractory (R/R) patients were eligible. Patients received venetoclax plus a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, orelabrutinib or pirtobrutinib) alone or combined with anti-CD20 monoclonal antibody (rituximab or obinutuzumab). Treatment selection and duration were determined by the treating physicians per routine clinical practice. Venetoclax was administered with standard ramp-up to mitigate tumor lysis syndrome (TLS) risk. Peripheral blood MRD (PB-MRD) was assessed at EOT+3 (3 months after end of treatment) by multiparameter flow cytometry with a sensitivity of 10-4.

Results

At cut-off date (July 27, 2026), 74 patients were included (CLL: 94.0%, SLL: 6.3%; TN: 77%, R/R: 23%). Median age was 53 years (range: 27-76) (18% ≥65 years). According to CLL-IPI, 16 patients (21.6%) were classified as high-risk and 22 (29.7%) as very high-risk, accounting for half of the cohort. Unmutated/mutated IGHV (56.8%/40.5%; 2.7% not available), unmutated/mutated TP53 (59.4%/29.7%; 10.8% not available), present/absent del17p (21.6%/68.9%; 9.4% not available) and present/absent complex karyotype (31.0%/51.3%; 17.5% not available) were reported.

Ven-base regimens included: doublet therapy group of ven+BTKi (50%), Triplet therapy group of ven+BTK+CD20mAb (50%). At the time of analysis, 14 patients are still on treatment. Median duration of Ven exposure was 14.9 months (range: 3.2-59.6). Six patients had Ven duration of <10 months: one R/R patient experienced progressive disease (PD) after 4.6 months of doublet therapy, two discontinued due to adverse events (AEs), one due to COVID-19, one due to other medical conditions, and one remained on treatment. The other three patients with PD all had ven duration >24 months. Patients with del(17p) and/or TP53 mutation had a higher prevalence in the triplet group (59.1%) compared to doublet group (45.5%). Similarly, unmutated IGHV was observed in 67.6% of patients in the triplet group versus 45.9% in the doublet group, suggesting a preference for treatment intensification in patients with high-risk genetic features.

Median follow up was 45.1 months overall, 48.3 months in doublet therapy group, and 40.1 months in triplet therapy group. The overall response rate (ORR) was 90.5% (67/74), with 81.1% (60) achieving ≥CR (or CR/CRi). ORR was 89.5% in the high/very high risk group and 90.6% in the low/mediate risk group. The progression-free survival (PFS) rate was 96.5% at 36 months and 93.7% at 48 months overall. PB-MRD at EOT+3 was assessed in 54 patients. uMRD was significantly more frequent in triplet therapy group (89.7%, 26/29) than in doublet therapy group (56.0%, 14/25; p=0.011). In patients with del(17p) and/or TP53 mutation, the uMRD rate was 73.7%, compared with 76.9% in those without these alterations. And the uMRD rates were 65.2% and 80.0% in patients with uIGHV and mIGHV, respectively. The safety profile will be included in the congress presentation. 

Conclusion

In this real-world cohort, both doublet and triplet ven-based combinations demonstrate high efficacy in Chinese CLL patients. The significantly higher EOT+3 uMRD rate observed with triplet therapy warrants further investigation in prospective studies to determine whether this translates into superior long-term PFS, particularly in high-risk patient subsets. Larger cohorts with longer follow-up are needed to validate these observations and to explore the optimal treatment intensification strategies for different CLL risk groups.

Yilin Kong: No relevant conflicts of interest to declare.